Seattle Genetics Q4 top line up 13%; soft guidance sinks shares, down 8% after hours

• Seattle Genetics (NASDAQ:SGEN) Q4 results ($M): Total Revenues: 105.3 (+12.6%); Product Sales: 70.8 (+12.4%).
• Net Loss: (55.1) (+121.8%); Loss/Share: (0.39) (+116.7%).
• 2017 Guidance: Revenues: $405M - 445M; ADCETRIS Sales: $280M - 300M; Collaboration Revenues: $75M - 90M; Royalty Revenues: $50M - 55M. Midpoint of revenue guidance represents less than 2% above 2016's $418.2M.